Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232(2):142–150. https://doi.org/10.1002/path.4280

Article  PubMed  PubMed Central  Google Scholar 

Sporikova Z, Koudelakova V, Trojanec R, Hajduch M (2018) Genetic markers in triple-negative breast Cancer. Clinical breast cancer 18(5):e841–e850. https://doi.org/10.1016/j.clbc.2018.07.023

Article  CAS  PubMed  Google Scholar 

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research : an official journal of the American Association for Cancer Research 13 (15 Pt 1):4429–4434. doi:https://doi.org/10.1158/1078-0432.CCR-06-3045

Chacon RD, Costanzo MV (2010) Triple-negative breast cancer. Breast cancer research : BCR 12 Suppl 2:S3. doi:https://doi.org/10.1186/bcr2574

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721–1728. https://doi.org/10.1002/cncr.22618

Article  PubMed  Google Scholar 

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina breast Cancer study. Jama 295(21):2492–2502. https://doi.org/10.1001/jama.295.21.2492

Article  CAS  PubMed  Google Scholar 

Hubalek M, Czech T, Muller H (2017) Biological subtypes of triple-negative breast Cancer. Breast care 12(1):8–14. https://doi.org/10.1159/000455820

Article  PubMed  PubMed Central  Google Scholar 

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 24(2):157–167. https://doi.org/10.1038/modpathol.2010.200

Article  Google Scholar 

Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27:16–25. https://doi.org/10.1016/j.coi.2014.01.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024):1565–1570. https://doi.org/10.1126/science.1203486

Article  CAS  PubMed  Google Scholar 

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148. https://doi.org/10.1016/j.immuni.2004.07.017

Article  CAS  PubMed  Google Scholar 

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TWG (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Annals of oncology : official journal of the European Society for Medical Oncology 26(2):259–271. https://doi.org/10.1093/annonc/mdu450

Article  CAS  Google Scholar 

Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T (2016) Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World journal of clinical oncology 7(5):387–394. https://doi.org/10.5306/wjco.v7.i5.387

Article  PubMed  PubMed Central  Google Scholar 

Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer immunology, immunotherapy : CII 60(7):909–918. https://doi.org/10.1007/s00262-011-1046-y

Article  CAS  PubMed  Google Scholar 

Adams TA, Vail PJ, Ruiz A, Mollaee M, McCue PA, Knudsen ES, Witkiewicz AK (2018) Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 31(2):288–298. https://doi.org/10.1038/modpathol.2017.126

Article  CAS  Google Scholar 

Caldwell C Jr, Johnson CE, Balaji VN, Balaji GA, Hammer RD, Kannan R (2017) Identification and validation of a PD-L1 binding peptide for determination of PDL1 expression in tumors. Sci Rep 7(1):13682. https://doi.org/10.1038/s41598-017-10946-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242. https://doi.org/10.1111/j.1600-065X.2010.00923.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA (2016) Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69(1):25–34. https://doi.org/10.1111/his.12904

Article  PubMed  Google Scholar 

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331

Article  CAS  PubMed  Google Scholar 

Atezolizumab Combo Approved for PD-L1-positive TNBC (2019). Cancer discovery 9 (5):OF2. doi:https://doi.org/10.1158/2159-8290.CD-NB2019-038

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, Investigators IM (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 21(1):44–59. https://doi.org/10.1016/S1470-2045(19)30689-8

Article  CAS  PubMed  Google Scholar 

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(16):2784–2795. https://doi.org/10.1200/JCO.2009.25.6529

Article  Google Scholar 

Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y (2016) Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat 158(1):1–9. https://doi.org/10.1007/s10549-016-3848-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hida AI, Ohi Y (2015) Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. Annals of oncology : official journal of the European Society for Medical Oncology 26(11):2351. https://doi.org/10.1093/annonc/mdv363

Article  CAS  Google Scholar 

Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H (2015) Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int 65(12):644–651. https://doi.org/10.1111/pin.12355

Article  PubMed  PubMed Central  Google Scholar 

Herrero-Vicent C, Guerrero A, Gavila J, Gozalbo F, Hernandez A, Sandiego S, Algarra MA, Calatrava A, Guillem-Porta V, Ruiz-Simon A (2017) Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience 11:759. https://doi.org/10.3332/ecancer.2017.759

Article  PubMed  PubMed Central  Google Scholar 

O'Loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, Figueiredo P, Floris G, Foschini MP, Heikkila P, Kulka J, Liepniece-Karele I, Regitnig P, Reiner A, Ryska A, Sapino A, Shalaby A, Stovgaard ES, Quinn C, Walsh EM, Zolota V, Glynn SA, Callagy G (2018) Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Res Treat 171(1):1–9. https://doi.org/10.1007/s10549-018-4825-8

Article